Center-Authored Papers

Filters: Author is Zonder, Jeffrey A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
Hussein MA, Bolejack V, Zonder JA, Durie BGM, Jakubowiak AJ, Crowley J, Barlogie B.  2009.  Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204).. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3510-7. Abstract
R
Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH et al..  2016.  A meta-analysis of multiple myeloma risk regions in African and European ancestry populations identifies putatively functional loci.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. Abstract
S
Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS et al..  2017.  A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.. Cancer. Abstract
Z
Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DEH, Singhal AK.  2011.  A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.. Blood. 120(3):552-559. Abstract
Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BGM, Barlogie B.  2010.  Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).. Blood. 116(26):5838-41. Abstract